Subscribe To
Apogee announces first participants dosed ahead of schedule in phase 1 trial of apg777, its novel half-life extended anti-il-13 antibody for the treatment of atopic dermatitis and other inflammatory d
preclinical data with APG777 demonstrate the potential for significantly improved dosing over standard ...
August 7, 2023, 11:30 am
Immunic reports 2q results; expects to be able to fund operations into 4q 2024
Immunic, Inc. said that at the end of its second quarter to June 30, 2023, it had cash, cash equivalents and investments of $77.3 million with which...
August 3, 2023, 9:18 am
Astrazeneca reveals a $1.0 billion deal with pfizer
AstraZeneca plc (LON: AZN) was in focus on Friday after the pharma giant announced a deal worth up to $1.0 billion with its U.S. peer Pfizer Inc (NYSE...
July 29, 2023, 6:07 pm
Astrazeneca unit strikes $1bn rare diseases deal with pfizer
AstraZeneca PLC's rare disease unit, Alexion, has unveiled a $1 billion agreement to acquire Pfizer's early-stage gene therapy portfolio, a strategic...
July 28, 2023, 2:41 am
Ipo update: apogee therapeutics proposes terms for $250 million ipo
Apogee Therapeutics, Inc. has filed proposed terms for a $250 million IPO. The firm is developing drug treatment candidates for atopic dermatitis, COP...
July 10, 2023, 5:33 pm
Instil bio announces oral presentation of itil-306 preclinical data at british society for gene and cell therapy annual conference
Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, f...
June 26, 2023, 8:38 pm
Terns pharmaceuticals highlights new preclinical data for tern-601 program in obesity at the ada’s 83rd annual scientific session and upcoming events
TERN-601 significantly improved glucose tolerance, suppressed food intake and slowed gastric emptying in a pre...
June 26, 2023, 8:05 pm
Biora therapeutics presents data on the biojet™ systemic oral delivery platform at the american diabetes association 83rd scientific sessions
An average bioavailability of 37% for a GLP-1 receptor agonist was achieved in animals SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) — Biora Therapeutic...
June 26, 2023, 10:00 am
Vir biotechnology presents new data evaluating the potential for vir-2218 and vir-3434 as therapies for chronic hepatitis b and hepatitis d
– Data from two ongoing clinical trials in people living with chronic hepatitis B infection suggest the combination of an antiviral with an immunomo...
June 24, 2023, 9:30 am
Pliant therapeutics presents data from its bexotegrast program at the european association for the study of the liver (easl) international liver congress™
Presentations highlight preclinical and clinical advancements of bexotegrast program in primary scleros...
June 23, 2023, 11:30 am
Poolbeg pharma consortium moves into important new phase as it develops a breakthrough oral vaccine
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said important preclinical work is starting on a programme ...
June 22, 2023, 2:40 am
Hepion pharmaceuticals to present two posters at easl international liver congress™ 2023
- preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcri...
June 15, 2023, 4:45 pm
The estée lauder companies to present novel scientific data at world congress of dermatology
ELC to Present Novel Scientific Data Spanning Emerging Research Areas and Clinical Progress to Promote Skin Health and Anti-aging at World Congress of...
June 14, 2023, 12:30 pm
Kymera therapeutics’ stat3 degrader kt-333 and irakimid degrader kt-413 demonstrate desired target knockdown and safety with continued dose escalation in ongoing phase i clinical trials
Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associ...
June 14, 2023, 6:30 am
Allakos presents preclinical data at eaaci hybrid congress 2023 highlighting lirentelimab and ak006 mechanisms of mast cell inhibition
– AK006 inhibits IgE mediated mast cell activation and shows similar IgE inhibitory activity as remibrutinib –– AK006 also inhibits non-IgE mast...
June 12, 2023, 11:02 am
Pyxis oncology: a high-stakes gambit in the battle against solid tumors
Pyxis Oncology is developing next-generation therapeutics, including antibody-drug conjugates and immuno-oncology programs, to target solid tumors res...
June 12, 2023, 2:59 am
Why shares of cullinan oncology jumped this week
Cullinan Oncology's lead therapy is zipalertinib, which is in a trial to treat non-small cell lung cancer. The company has a deep pipeline and publish...
June 9, 2023, 4:07 pm
Biora therapeutics to present preclinical data on the biojet™ systemic oral delivery platform at the 59th annual meeting of the european association for the study of diabetes
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, to...
June 8, 2023, 9:00 am
Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in science advances demonstrating potent in vitro and in vivo antimicrobial activity
Novel antibiotics were developed by Spexis in close collaboration with Professor Oliver Zerbe’s group at the University of Zurich with substantial f...
June 7, 2023, 5:15 am
Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in science advances demonstrating potent in vitro and in vivo antimicrobial activity
Novel antibiotics were developed by Spexis in close collaboration with Professor Oliver Zerbe’s group at the University of Zurich with substantial f...
June 7, 2023, 5:15 am